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Edited by Robert BaroukiAbstract Like us, our cells have evolved strategies to cope with,
and sometimes utilize, stress. Molecular analyses of plasma cell
biogenesis, lifestyle and death suggest that protein synthesis-
dependent stress is utilised to integrate diﬀerentiation, function
and lifespan control. Plasma cells are short-lived professional
secretory cells, each of them capable of releasing several thou-
sands antibodies per second. Their diﬀerentiation from B lym-
phocytes entails the spectacular enlargement of the
endoplasmic reticulum (ER), ﬁnalized to sustain massive Ig pro-
duction. Nonetheless, symptoms of ER stress are evident, and the
UPR-related transcription factor XBP-1 is essential for diﬀeren-
tiation. Surprisingly, the development of such an eﬃcient factory
is matched by a decrease in proteasomes. The unbalanced load/
capacity ratio leads to accumulation of polyubiquitinated mole-
cules and predisposes plasma cells to apoptosis. Exuberant anti-
body secretion imposes considerable stress on metabolic and
redox homeostasis. Collectively, these stressful conditions may
link plasma cell death to antibody production, providing a molec-
ular counter for secreted molecules, as well as an explanation for
the peculiar sensitivity of myeloma cells towards proteasome
inhibitors.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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‘‘Lavorare stanca’’, i.e. working stresses. Although conceived
by the prominent italian poet Cesare Pavese as the title of his
ﬁrst poetry collection in 1936 [1], this sentence applies perfectly
to cell biology. During their lifetime, cells experience a variety
of stressful conditions, often generated by their own metabo-
lism. As a result, most metabolic pathways operating in living
cells are equipped with stringent checkpoint mechanisms,
which can elicit rapid compensatory responses. For example,
cells can resist to increased generation of reactive oxygen spe-Abbreviations: DRiPs, defective ribosomal products; ER, endoplasmic
reticulum; ERAD, ER associated degradation; Ig, immunoglobulin;
MM, multiple myeloma; PDI, protein disulﬁde isomerase; PI, protea-
some inhibitors; RDP, rapidly degraded polypeptides; ROS, reactive
oxygen species; UPR, unfolded protein response
*Corresponding author. Fax: +39 02 2643 4723.
E-mail addresses: simone.cenci@hsr.it (S. Cenci), roberto.sitia@hsr.it
(R. Sitia).
0014-5793/$32.00  2007 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2007.04.031cies (ROS) or changes in temperature – examples of cytotoxic
stress – by expanding their buﬀering capacity and/or arrays of
chaperones. The synthesis and secretion of proteins also gener-
ate stress, particularly in professional secretory cells. They do
so consuming energy and aminoacids, unbalancing the redox
and generating toxic molecules and byproducts. In response
to genetic lesions – genotoxic stress – cells can arrest the cell
cycle to allow DNA repair.
In multicellular organisms, if the adaptive measures taken
are insuﬃcient to cope with the underlying stress, a functional
threshold exists that elicits a radical change in strategy, activat-
ing programmed cell death to defend the organism. An exciting
challenge for cell biologists is understanding the molecular
mechanisms that sense and transduce stress signals into adap-
tive responses, as well as the switches that take irreversible
death decisions, the prototypic maladaptive response, at least
from the cell’s point of view. This endeavor has profound
implications in biotechnology, where much can be learned to
improve the eﬃciency of bioreactors, and in medicine, since
the pathogenesis of many diseases involves disturbances in cel-
lular stress responses. In this essay, we shall discuss some re-
cent ﬁndings concerning the exploitation of stress responses
in the biogenesis, function and death of plasma cells, one of
the most eﬃcient protein factories amongst mammalian cells.2. The stress of protein synthesis
Protein synthesis can be quite stressful, particularly for
secretory proteins that are released into the extracellular space.
Their synthesis, folding, quality control and transport require
large amounts of metabolites and energy. Some specialized
secretory cells release humongous amounts of proteins. These
can exceed the weight of the cell in a few days. Secreting a pro-
tein implies a net loss of aminoacids, which must be replen-
ished by synthesis and/or import. The energy investments
necessary for maintaining adequate aminoacids pools are fur-
ther increased by the huge levels of ATP consumed for the syn-
thesis and folding of the proteins in the endoplasmic reticulum
(ER), and the numerous membrane fusion and ﬁssion events
utilized for their delivery to the extra-cellular space.
Furthermore, since secretory proteins are rich in disulﬁde
bonds, their production can generate oxidative stress to insert
and reshuﬄe these covalent linkages such that their proper
arrangement is attained [2]. In mammalian cells, the capacity
of the oxidative protein folding machinery depends on two con-
served resident oxidases, Erola and Erolb [3–6]. Whilst the for-
mer is expressed in most cell types, the latter is constitutivelyblished by Elsevier B.V. All rights reserved.
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ER stress [4,6]. The yeast ortholog Erolp is a ﬂavoprotein that
utilizes O2 as a terminal electron acceptor. Elegant in vitro
experiments convincingly demonstrated that H2O2 is produced
in equimolar quantities to the number of disulﬁdes formed
[7,8]. Recent work in yeast linked disulﬁde bond formation to
ROS by-production [2]. Other groups had diﬃculties in moni-
toring H2O2 production in yeast cells [9], suggesting that alter-
native electron acceptors may exist in vivo. Since human Erol
molecules can complement Erolp defective yeast cells [3,4],
the basic mechanisms of oxidative folding appear to be con-
served throughout evolution. Therefore, it would be extremely
important to conﬁrm that oxidative protein folding causes per-
oxide formation also in mammalian cells (Fig. 1), and if so in
what molar ratio. Peroxides could induce signaling and/or oxi-
dative stress, thus continuously reporting on the metabolic
activity of the ER as a protidosynthetic compartment. Should
H2O2 be a byproduct of disulﬁde bond formation, redox
homeostasis could be selectively targeted pharmacologically
or genetically by silencing or overexpressing peroxiredoxins
and other scavenger molecules.
In addition to the metabolic implications listed above, pro-
tein synthesis could generate additional stress, because the pro-
cesses of protein folding are intrinsically error-prone and toxic
conformers that tend to aggregate in the crowded cell compart-
ments are bound to be formed. To reduce the risks of proteo-
toxicity, a vast array of specialized chaperones and enzymes
are present in our cells, strategically located where folding
takes place (cytosol, ER, and mitochondria). Nevertheless,
also under normal conditions, a proportion of newly synthe-
sized proteins do not attain their native conformation. As
these species can be toxic for cells, they are rapidly degraded,
generally by cytosolic proteasomes [10]. These multimolecular
structures dispose also of regulatory proteins and signaling ele-
ments that are intrinsically short-lived, thereby playing a cru-
cial role in diﬀerent processes: cell cycle progression (e.g.
cyclins, myc), cell growth and gene expression (c-jun, fos,
and b-catenin), signaling (HIF1a, src, protein kinase C, andReduced
Cargo (Ig) 
Oxidised
Cargo (Ig) O2
H2O2 Ero1αRED
FAD
Ero1αOX
Isomerisation
105 disulfides per sec
in plasma cells, only
to sustain IgM production
105 H2O2 per sec?
PDIRED
PDIOX
UPR
Ero1β
ERAD
Fig. 1. Oxidative protein folding in the ER and generation of
peroxides. The production of secretory proteins, rich in disulﬁde
bonds, is a potential source of oxidative stress. In vitro studies with
puriﬁed yeast Erolp demonstrated equimolar disulﬁde/H2O2 ratios,
with reactive oxygen species (ROS) as byproducts [7,8]. Two conserved
ER resident oxidases, Ero1a and Ero1b, are responsible for oxidative
protein folding, the latter being expressed in secretory cell types and
upon ER stress, possibly generated by accumulation of reduced,
misfolded cargo proteins when Ero1a does not satisfy the oxidative
demand. In Ig-secreting plasma cells, the amount and structure of
cargo predict a striking generation of peroxides. Additional redox
stress could be caused by extensive disulﬁde reduction in ER cargo
proteins targeted to ERAD [2,67].IkBa). As a result, toxicity of misfolded proteins can derive
not only from aggregation or display of novel surface determi-
nants leading to illegitimate interactions, but also by burden-
ing proteasomes and competitively inhibiting the degradation
of other species, thereby altering many cellular processes
[11]. Another key function of proteasomes is that of generating
peptide ligands for MHC class I molecules to be presented to T
lymphocytes that roam the body to check for the presence of
foreign products [12].3. Proteasomes as crossroads against proteotoxicity
Recent pioneering studies revealed that a vast proportion of
newly made proteins are degraded by proteasomes in the ﬁrst
minutes of their existence. These species, called DRiPs for
defective ribosomal products or RDPs for rapidly degraded
polypeptides, can reach the astonishing ﬁgure of 30% in some
primary euploid mammalian cells [13,14]. While the precise
dimensions of this phenomenon are a matter of debate [15],
its teleology was initially related to the need of rapidly present-
ing antigenic peptides derived from intensely translated pro-
teins, an advantage in the evolutionary ﬁght against viruses
[12]. Rapid degradation of newly made proteins may also reﬂect
the metabolic state of the cell, representing a measure to main-
tain the pool of free aminoacids during starvation, a condition
that often accompanies certain experimental setups [16]. What-
ever their origin, RDPsmay dramatically increase the workload
of proteasomes, and create potentially stressful conditions by
competing with the ongoing degradation of other proteins.
Besides RDPs, proteasomes can ﬁnd themselves overbur-
dened when genetic and environmental factors (i.e. mutations
or lack of cofactors) increase the frequency of aberrant pro-
teins. Such situations are encountered in many conformational
diseases, a broad category encompassing neurodegeneration,
diabetes, genetic disorders, and others [17,18].
The ubiquitin–proteasome system selectively eliminates mis-
folded or damaged proteins not only from the cytosol and nu-
cleus, where proteasomes reside, but also from the ER.
Secretory proteins recognized as aberrant by ER quality con-
trol are retro-translocated across the ER membrane and dis-
patched to the cytosol for degradation by proteasomes (ER
associated degradation, ERAD) [18]. Therefore, proteasomes
represent the ﬁrst line of defense against proteotoxicity [10].
Moreover, these complexes are crucial crossroads in respond-
ing to proteotoxic stresses and transmitting them across the
two main protein-folding compartments of eukaryotic cells.
It has been shown that the accumulation of a polyglutamine
protein in the cytosol can overload proteasomes. Since the ret-
ro-translocation of many ERAD substrates is coupled to deg-
radation [19], numerous aberrant proteins accumulate in the
ER of cells with inactive proteasomes [20] and activate the un-
folded protein response (UPR), which may ultimately result in
cell death [21–24].4. Regulating proteasome levels
In principle, as proteasomes serve an essential quality control
mechanism, their abundance and activity should be propor-
tional to the workload. In the presence of increased protein
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therefore, a cell may want to activate strategies that empower
proteasomal degradation. According to the existence of regula-
tory networks, mammalian cells respond to pharmacological or
genetic proteasomal knock-down by activating the coordinated
synthesis of the proteasomal subunits in the proper stoichiom-
etry [25,26]. An elegant mechanism for controlling proteasome
biogenesis has been described in yeast. In Saccharomyces cere-
visiae the transcription factor Rpn4 controls all the genes
encoding proteasome subunits by activating a common cis-act-
ing element named PACE (for proteasome-associated control
element) [27]. Feed-back regulation is guaranteed by the fact
that Rpn4 is itself a short-lived proteasome substrate [28,29].
Rather little is known on the mechanisms that regulate protea-
some biogenesis in metazoans, apart from the well described ef-
fects of interferon y on the three subunits speciﬁcally found as
part of immunoproteasomes of professional antigen-presenting
cells [30–32]. Although all mammalian 26S subunit RNAs
increase in a concerted fashion upon proteasomal blockade,
neither an ortholog of Rpn4 nor conserved DNA regulatory
elements has been identiﬁed so far in the promoter of mamma-
lian proteasome genes. Intriguingly, the 5 0 untranslated region
(UTR) are conserved in mammals and required for mRNA
induction of proteasome genes in Drosophila melanogaster,
although no obvious consensus sequence emerges from com-
paring diﬀerent regulated genes [26]. These results provide a
framework for investigating the mechanisms regulating protea-
some biogenesis.
Are there other physiological conditions that regulate protea-
some biogenesis? Some data suggest that this could be the case.
For instance, HSF1, the transcriptional inducer of the heat
shock response (HSR), has been shown to indirectly induce
the coordinated expression of many proteasome subunits in
yeast [33], suggesting that stress conditions that pose increased
degradative demands may upregulate proteasome biogenesis.
A progressive loss of proteasome activity has been proposed
to play a role in a model of yeast aging [34]. However, there
is little evidence for physiopathological conditions regulating
proteasome biogenesis in mammals, apart from reports on
the association of impaired proteasome activity and expression
with aging in the rat liver and human T lymphocytes [35] (and
references therein). An intriguing link has been described be-
tween proteasome levels and the Nrf2–Keap1 pathway. Antiox-
idant response elements (ARE) present in the regulatory
sequences of many proteasome subunits seem to guide protea-
some synthesis in response to indirect antioxidants [36].
Therefore, diﬀerent cells and tissues may be equipped with
diﬀerent proteasome complements, possibly meeting diﬀerent
degradative needs, bound to speciﬁc cellular functions or envi-
ronmental conditions. It is possible that cell types carrying out
massive protein synthesis express higher proteasome levels.
One case would be that of plasma cells, the Ig-secreting eﬀector
of the immune system. The next paragraph will dissect this un-
ique model, in which a spectacular eﬃciency as a protein fac-
tory and a surprising insuﬃciency in the protein disposal
apparatus coexist, depicting a scenario of cellular overload.T
Fig. 2. A dual role of stress in plasma cell diﬀerentiation? In a ﬁrst
phase, adaptation to stress may turn useful for survival and develop-
ment, so as to meet the demanding secretory goals. In a second phase,
diﬀerent types of stress (ER stress, proteotoxicity, redox imbalance,
etc.) may synergise to facilitate, and eventually execute, cell death.5. The plasma cell paradigm
Plasma cells, real specialists in antibody production, repre-
sent an ideal model to investigate the cellular dynamics of pro-teosynthetic stress. Their diﬀerentiation from small resting B
lymphocytes into Ig-secreting cells entails a series of spectacu-
lar genetic and functional changes, ﬁnalized to producing spe-
ciﬁc antibodies in adequate amounts at the proper time [37,38].
Upon encounter with antigen, long-lived B lymphocytes acti-
vate a profound functional and structural metamorphosis that,
in few days, leads to diﬀerentiation into a mature plasma cell, a
terminally diﬀerentiated element capable of secreting thousand
Ig molecules per second [18,39]. The vast majority of plasma
cells are short-lived so as to limit the antibody response. The
mechanisms leading to programmed death of plasma cells
are still unclear (Fig. 2).
5.1. The birth of a plasma cell: stressed to work
The late phases of B to plasma cell diﬀerentiation are char-
acterized by the accumulation of XBP-1 [40], a transcription
factor essential for plasma cell diﬀerentiation [41,42]. XBP-1
is a key component of the UPR, a multifaceted signaling cas-
cade evolved to adapt to changing biosynthetic needs or to
environmental conditions. If the synthesis of secretory proteins
exceeds the capacity of the ER factory, speciﬁc sensors activate
a series of measures that collectively upgrade the ER folding
capacity [43]. Somehow unexpectedly, during plasma cell dif-
ferentiation ER resident proteins are synthesized before Ig
accumulation [39,40]. These observations suggest that the acti-
vation of certain UPR elements may be driven by speciﬁc
developmental program(s), rather than being solely a conse-
quence of cargo accumulation. Whatever the mechanism(s)
that activate and sustain ER stress, the links between redox
imbalances, UPR and NF-kB activation [44–48] could provide
a feed-forward system whereby the increased production of
secretory proteins facilitates initially the survival and develop-
ment of mature plasma cells.
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A prolonged UPR can lead to intrinsic apoptosis. Many are
the potential mechanisms proposed: suppressed Bcl-2 expres-
sion and sensitization to ROS via Chop/GADD153, activation
of ER stress-speciﬁc caspases (caspase 12 in mice, caspase 4 in
humans), mitochondrial activation by ER calcium release, and
activation of JNK [21,23,24,49–57]. It was thus surmised
by many that the intense synthetic activity of plasma cells
might activate apoptosis through the UPR. However, the
PERK-Chop sub-pathway does not seem to be critical for
plasma cell activity [58] (Masciarelli S. et al, manuscript in
preparation).
By employing diﬀerent in vitro models of plasma cell diﬀer-
entiation (namely, the LPS-inducible B lymphoma I.29l+,
and primary spleen B cells stimulated with either LPS or
anti-CD3-activated T cells), we have recently reported that
proteasome capacity dramatically decreases along plasma cell
diﬀerentiation [58]. In striking correlation with impaired prote-
olysis, polyubiquitinated proteins accumulate, death-inducing
proteins are stabilized, presumably via competitive inhibition
of their degradation, and apoptotic sensitivity to proteasome
inhibitors ensues, prior to spontaneous apoptosis [58]. Attest-
ing to a cause–eﬀect relationship between proteasomal over-
load and death, similar events can be recapitulated by over-
expressing an orphan l chain, a proteasome substrate deriving
from the ER, in a non-lymphoid tumor line [58].
Importantly, the fall in proteasomal levels is even more strik-
ing when plasma cell diﬀerentiation is obtained in vivo by
injecting LPS in mice. Furthermore, in line with the increased
apoptotic sensitivity to proteasome inhibitors during plasma
cell diﬀerentiation [58], both T cell-dependent and T-indepen-
dent antigen-speciﬁc antibody responses, are signiﬁcantly
blunted by treatment of immunized mice with PS-341/bortezo-
mib (P. Cascio et al., manuscript in preparation).
Additional elements could make plasma cells susceptible to
apoptosis. For instance, cells secreting large amounts of Ig
molecules could undergo metabolic or redox imbalances. In
their late diﬀerentiation phases, before the apoptotic program
is activated, primary plasma cells produce large amounts of
IgM (about 103/cell/s). It follows that up to 105 disulﬁdes are
formed per second in each plasma cell, solely to sustain IgM
production. In agreement with an increased need for oxidative
power, both Erola and Erolb are upregulated during plasma
cell diﬀerentiation [40] (M. Otsu et al., unpublished observa-
tion). That diﬀerentiating B cells indeed undergo oxidative
stress is indicated by the increase in peroxiredoxins [40] and
activation of Nrf2 and downstream genes of the antioxidant
response (S. Nerini et al., unpublished observations). In addi-
tion, we have obtained evidence for tight links and synergies
between redox and proteasomal blockade (Nerini et al., sub-
mitted). Eﬀorts are being taken to determine whether perox-
ides are formed as byproduct of exuberant Ig synthesis. In
addition to redox imbalances, aminoacid supply or energy pro-
duction may become limiting during terminal plasma cell dif-
ferentiation. Eight ·106 aminoacids must be synthesized or
imported each second to compensate for IgM secretion. IgM
being planar disks 36 nm wide and 4 nm thick, an impressive
number of vesicles must be produced to warrant their trans-
port, and as many to recycle the intracellular membrane com-
partments. Wide-scope studies are required to describe the
metabolic proﬁle of plasma cells, with emphasis on energy pro-
duction, aminoacid import and synthesis, aiming at identifyingmetabolic correlates hallmarking plasma cell diﬀerentiation
and death decisions.
In summary, short-lived plasma cells display a redundant ar-
ray of pathways that may cause their death. In particular,
while proteasomal insuﬃciency profoundly perturbs protein
homeostasis and lowers the apoptotic threshold, toxic byprod-
ucts of intensive Ig synthesis may accumulate as secretion
proceeds, in an exponentially less favorable energetic and
metabolic cellular environment, so as to provide the coup de
graˆce that shuts oﬀ the life program of Ig factories
(Fig. 2).6. A counter for the humoral response?
The load vs capacity model leads to a few interesting predic-
tions and speculations. It may oﬀer a sensible strategy to end
the immune response, along with an explanation for the appar-
ent paradox of proteasome insuﬃciency in plasma cells. In-
deed, the decreased expression of proteasomes whilst the cell
specializes into a secretory phenotype seems at ﬁrst a paradox.
What is the teleology of such a programme? One potential
explanation derives from an immune perspective. The humoral
response is ended by apoptotic elimination of the vast majority
of plasma cells, after they have produced suitable amounts of
antibodies. The system may be based on a timer or a counter.
In principle, the latter may result in better tuning of antibody
responses. An intracellular sensor of the work accomplished
could transduce intrinsic stimuli and launch death when a
functional threshold is met. The case of plasma cells seems
to ﬁt in this model. By engineering a bottleneck in an otherwise
eﬃcient quality control strategy devoted to Ig folding and
assembly, plasma cells may have evolved a mechanism to
count the work accomplished, and predispose themselves to
die. A selective accumulation of certain protein species, like
the pro-apoptotic Bc1-2 relatives Bax and Bim, or the NF-
kB counteractor IkBa, may simply facilitate death, the coup
de graˆce being provided by a number of mechanisms likely
to be active in plasma cells: oxidative stress, UPR, ER calcium
release, etc. Each of these processes has been shown to be suf-
ﬁcient to trigger death in a variety of cell and animal systems.
Together, they may provide plasma cells with a powerful
redundancy, and ensure apoptosis.
Further predictions and questions arise from this model that
could be tested in the future.
Marginal zone spleen B cells are strategically located to ini-
tiate a fast and intense antibody response to blood-borne viral
and bacterial agents. Indeed, these cells are programmed to
diﬀerentiate more rapidly (within one day) into Ig-secreting
cells. Being short-lived as well, these plasma cells oﬀer an
intriguing experimental model to test the role of load–capacity
dynamics in determining plasma cell lifespan [59,60].
Do long-lived plasma cells diﬀer from short-lived Ig-secre-
tors in their intrinsic eﬃciency of coping with protein disposal
and cytotoxic stress? The pro-survival eﬀects of local factors
that promote homing of long-lived plasma cells in bone mar-
row niches could be, at least partially, linked to an adaptation
of proteasomes or other stress responses. It would also be
interesting to address whether professional long-lived secretory
cells, such as endocrine cell types, are equipped with more or
more eﬃcient proteasomal complements.
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Errors in the regulation of plasma cell lifespan can lead to
dramatic consequences: a failure to diﬀerentiate or premature
demise would cause immune deﬁciencies. In contrast, defective
cell death would lead to autoimmune diseases and tumors.
Multiple myeloma (MM) is caused by uncontrolled prolifera-
tion of a plasma cell clone that produces high amounts. The
neoplastic transformation occurs in cells that already encoun-
tered the antigen in germinal centers, and migrate to the bone
marrow, where they ﬁnd a microenvironment suitable for their
growth [61,62]. Recently, proteasome inhibitors (PI, e.g. PS-
341, Velcade) proved highly eﬃcient and selective against
MM, and are currently in phase IV clinical trial. Their anti-tu-
mor eﬀects owe primarily to their ability to prime apoptosis in
MM cells, but the underlying mechanisms are still unclear.
A large clinical trial demonstrated a prolongation of overall
survival, but not all patients enrolled responded. The reasons
for the diverse susceptibility remain unexplained.
The load vs capacity model oﬀers a potential explanation,
reinforced by recent results demonstrating correlations be-
tween the extent of protein production and sensitivity to bort-
ezomib [63,64].
A model thus emerges of exploiting cytotoxic stress against
tumors. The novel, underlying perspective is that apoptotic re-
sponses to cytotoxic stress are functional in tumors, whereas
those to genotoxic stress are often disabled. Moreover, tumors
are more exposed to cytotoxic stress than normal cells, thereby
providing selectivity [65].
Further dissecting the pathways whereby the synthetic load
provides normal and neoplastic plasma cells with sensitivity
to proteasome inhibition could lead to the identiﬁcation of
new targets in the proteasome-dependent stress/apoptosis re-
sponses, and translate into improved diagnostic and therapeu-
tic protocols for MM and other ‘stressable’ tumors. So, some
secretory cells would probably subscribe to Bertrand Russell’s
essay ‘‘In praise of idleness’’ (1932) [66].
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